Sweet syndrome associated with hydralazine-induced Lupus erythematosus

Todd V. Cartee, Suephy C. Chen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Sweet syndrome (SS) is a distinctive but poorly understood clinical syndrome, which likely represents an immunologic reaction pattern to a wide range of underlying or preceding conditions, including viral illnesses, inflammatory bowel disease, and malignancies. We report the case of a patient who presented with an acute eruption that was clinically and histologically consistent with SS. The patient also met diagnostic criteria for systemic lupus erythematosus with serositis, stomatitis, positive antinuclear antibody (ANA), and positive anti-double-stranded DNA antibodies. Additionally, positive antihistone antibodies and exposure to hydralazine supported the specific diagnosis of drug-induced lupus erythematosus, and we concluded that his SS was a manifestation of hydralazine-induced lupus. We also briefly review the precedence for this unusual dual diagnosis in the literature.

Original languageEnglish (US)
Pages (from-to)121-124
Number of pages4
JournalCutis
Volume89
Issue number3
StatePublished - Mar 1 2012

Fingerprint

Sweet Syndrome
Hydralazine
Serositis
Dual (Psychiatry) Diagnosis
Stomatitis
Antibodies
Antinuclear Antibodies
Inflammatory Bowel Diseases
Systemic Lupus Erythematosus
DNA
Pharmaceutical Preparations
Neoplasms

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Cartee, Todd V. ; Chen, Suephy C. / Sweet syndrome associated with hydralazine-induced Lupus erythematosus. In: Cutis. 2012 ; Vol. 89, No. 3. pp. 121-124.
@article{2656edfdebf44e769122b1232de69b2b,
title = "Sweet syndrome associated with hydralazine-induced Lupus erythematosus",
abstract = "Sweet syndrome (SS) is a distinctive but poorly understood clinical syndrome, which likely represents an immunologic reaction pattern to a wide range of underlying or preceding conditions, including viral illnesses, inflammatory bowel disease, and malignancies. We report the case of a patient who presented with an acute eruption that was clinically and histologically consistent with SS. The patient also met diagnostic criteria for systemic lupus erythematosus with serositis, stomatitis, positive antinuclear antibody (ANA), and positive anti-double-stranded DNA antibodies. Additionally, positive antihistone antibodies and exposure to hydralazine supported the specific diagnosis of drug-induced lupus erythematosus, and we concluded that his SS was a manifestation of hydralazine-induced lupus. We also briefly review the precedence for this unusual dual diagnosis in the literature.",
author = "Cartee, {Todd V.} and Chen, {Suephy C.}",
year = "2012",
month = "3",
day = "1",
language = "English (US)",
volume = "89",
pages = "121--124",
journal = "Cutis",
issn = "0011-4162",
publisher = "Quadrant Healthcom Inc.",
number = "3",

}

Sweet syndrome associated with hydralazine-induced Lupus erythematosus. / Cartee, Todd V.; Chen, Suephy C.

In: Cutis, Vol. 89, No. 3, 01.03.2012, p. 121-124.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sweet syndrome associated with hydralazine-induced Lupus erythematosus

AU - Cartee, Todd V.

AU - Chen, Suephy C.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Sweet syndrome (SS) is a distinctive but poorly understood clinical syndrome, which likely represents an immunologic reaction pattern to a wide range of underlying or preceding conditions, including viral illnesses, inflammatory bowel disease, and malignancies. We report the case of a patient who presented with an acute eruption that was clinically and histologically consistent with SS. The patient also met diagnostic criteria for systemic lupus erythematosus with serositis, stomatitis, positive antinuclear antibody (ANA), and positive anti-double-stranded DNA antibodies. Additionally, positive antihistone antibodies and exposure to hydralazine supported the specific diagnosis of drug-induced lupus erythematosus, and we concluded that his SS was a manifestation of hydralazine-induced lupus. We also briefly review the precedence for this unusual dual diagnosis in the literature.

AB - Sweet syndrome (SS) is a distinctive but poorly understood clinical syndrome, which likely represents an immunologic reaction pattern to a wide range of underlying or preceding conditions, including viral illnesses, inflammatory bowel disease, and malignancies. We report the case of a patient who presented with an acute eruption that was clinically and histologically consistent with SS. The patient also met diagnostic criteria for systemic lupus erythematosus with serositis, stomatitis, positive antinuclear antibody (ANA), and positive anti-double-stranded DNA antibodies. Additionally, positive antihistone antibodies and exposure to hydralazine supported the specific diagnosis of drug-induced lupus erythematosus, and we concluded that his SS was a manifestation of hydralazine-induced lupus. We also briefly review the precedence for this unusual dual diagnosis in the literature.

UR - http://www.scopus.com/inward/record.url?scp=84860826062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860826062&partnerID=8YFLogxK

M3 - Article

C2 - 22530328

AN - SCOPUS:84860826062

VL - 89

SP - 121

EP - 124

JO - Cutis

JF - Cutis

SN - 0011-4162

IS - 3

ER -